SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001610618-24-000087
Filing Date
2024-06-03
Accepted
2024-06-03 16:36:48
Documents
8
Period of Report
2024-07-18

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE PROXY STATEMENT cdtxdef14a06-03x2024.htm DEF 14A 972769
2 cdtx_2024xproxyxpvpxnla.jpg GRAPHIC 657256
3 cdtx_2024xproxyxpvpxtsra.jpg GRAPHIC 677481
4 cdtx_proxycardxpagex1a.jpg GRAPHIC 2546229
5 cdtx_proxycardxpagex2a.jpg GRAPHIC 1788162
6 cdtx_proxycardxpagex3a.jpg GRAPHIC 2366342
7 cdtx_proxycardxpagex4a.jpg GRAPHIC 1787931
8 cdtxlogoa13a.jpg GRAPHIC 46741
  Complete submission text file 0001610618-24-000087.txt   14544632
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

IRS No.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36912 | Film No.: 241014254
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)